Celltrion Biosimilar Package Is Strong, But How Many Indications Will It Get?

This article was originally published in The Pink Sheet Daily

05 Feb 2016
News

Sue Sutter @PinkSheetSutter sue.sutter@informa.com

Executive Summary

Like Zarxio before it, Inflectra is coming before an advisory committee having received a glowing review from FDA staff; the key question seems to be how many of Remicade's indications will it be able to extrapolate.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

United States

Subjects
Advisory Committees

Related Companies

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical United States Advisory Committees

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS079181

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS079181

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Celltrion Biosimilar Package Is Strong, But How Many Indications Will It Get?

News

Executive Summary

Topics

Related Companies

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert